Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 237437, 7 pages
http://dx.doi.org/10.1155/2014/237437
Review Article

Role of PET and SPECT in the Study of Amyotrophic Lateral Sclerosis

1Positron Emission Tomography Centre IRMET S.p.A., Euromedic Inc., V. O. Vigliani 89/A, 10136 Turin, Italy
2PET Pediatric AIMN InterGroup, V. O. Vigliani 89/A, 10136 Turin, Italy
3Institute of Cognitive Sciences and Technologies, National Research Council, Piazzale Aldo Moro 7, 00185 Rome, Italy
4Nuclear Medicine Unit, Department of Clinical and Experimental Internistic “F. Magrassi, A. Lanzara”, Seconda Università di Napoli, Vico Luigi de Crecchio 16, 80138 Naples, Italy
5Nuclear Medicine Unit, Department of Biomedical Sciences and of Morphological and Functional Images, University of Messina, Via Consolare Valeria 1, 98125 Messina, Italy
6Department of Nuclear Medicine, Karolinska University Hospital, Solnavägen 1, Solna, 171 77 Stockholm, Sweden
7Department of Neuroradiology, San Giovanni Battista-OIRM-S.Anna-CTO Hospital, Via Cherasco 15, 10126 Turin, Italy

Received 5 February 2014; Accepted 13 March 2014; Published 10 April 2014

Academic Editor: Fan-Rong Liang

Copyright © 2014 Angelina Cistaro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. B. Cannon, “Organization for physiological homeostasis,” Physiological Reviews, vol. 9, pp. 399–431, 1929. View at Google Scholar
  2. M. Ereshefsky, “Defining “health” and “ disease”,” Studies in History and Philosophy of Science C :Studies in History and Philosophy of Biological and Biomedical Sciences, vol. 40, no. 3, pp. 221–227, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. S. P. Jackson and J. Bartek, “The DNA-damage response in human biology and disease,” Nature, vol. 461, no. 7267, pp. 1071–1078, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Mansi, “Ich bin ein Molekularmediziner (how much CT and nuclear medicine in molecular CT?),” European Journal of Nuclear Medicine and Molecular Imaging, vol. 36, no. 3, pp. 531–532, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. G. L. Cascini, V. Cuccurullo, O. Tamburrini, A. Rotondo, and L. Mansi, “Peptide imaging with somatostatin analogues: more than cancer probes,” Current Radiopharmaceuticals, vol. 6, pp. 36–40, 2013. View at Google Scholar
  6. A. Cistaro, N. Quartuccio, S. Vesco et al., “Positron emission tomography,” Ophthalmology, vol. 119, pp. 1496–1497, 2012. View at Google Scholar
  7. S. L. Kitson, V. Cuccurullo, T. S. Moody, and L. Mansi, “Radionuclide antibody-conjugates, a targeted therapy towards cancer,” Current Radiopharmaceuticals, vol. 6, pp. 57–71, 2013. View at Google Scholar
  8. M. Benadiba, G. Luurtsema, L. Wichert-Ana, C. A. Buchpigel, and G. Busatto Filho, “New molecular targets for PET and SPECT imaging in neurodegenerative diseases,” Revista Brasileira De Psiquiatria, vol. 34, pp. S125–S136, 2012. View at Google Scholar
  9. L. Mansi, A. Ciarmiello, and V. Cuccurullo, “PET/MRI and the revolution of the third eye,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, pp. 1519–1524, 2012. View at Google Scholar
  10. V. Cuccurullo, G. L. Cascini, O. Tamburrini, A. Rotondo, and L. Mansi, “Bone metastases radiopharmaceuticals: an overview,” Current Radiopharmaceuticals, vol. 6, pp. 41–47, 2013. View at Google Scholar
  11. V. Cuccurullo, G. L. Cascini, and L. Mansi, “Structural, pathophysiological and clinical aspects of diagnostic imaging in breast recurrence: the breast after treatment,” The Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 57, pp. 322–331, 2013. View at Google Scholar
  12. A. Cistaro, N. Quartuccio, A. Mojtahedi et al., “Prediction of 2 years-survival in patients with stage I and II non-small cell lung cancer utilizing (18)F-FDG PET/CT SUV quantification,” Radiology and Oncology, vol. 47, pp. 219–223, 2013. View at Google Scholar
  13. N. Quartuccio, G. Treglia, M. Salsano et al., “The role of Fluorine-18-Fluorodeoxyglucose positron emission tomography in staging and restaging of patients with osteosarcoma,” Radiology and Oncology, vol. 47, pp. 97–102, 2013. View at Google Scholar
  14. A. Cistaro, N. Quartuccio, L. Mansi, A. Signore, M. Dolci, and G. Treglia, “The role of positron emission tomography in Inflammatory bowel disease,” European Journal of Inflammation, vol. 10, pp. 251–256.
  15. S. Morbelli, R. Perneczky, A. Drzezga et al., “Metabolic networks underlying cognitive reserve in prodromal Alzheimer disease: a European Alzheimer disease consortium project,” Journal of Nuclear Medicine, vol. 54, pp. 894–902, 2013. View at Google Scholar
  16. G. Giovacchini, F. Squitieri, M. Esmaeilzadeh, A. Milano, L. Mansi, and A. Ciarmiello, “PET translates neurophysiology into images: a review to stimulate a network between neuroimaging and basic research,” Journal of Cellular Physiology, vol. 226, no. 4, pp. 948–961, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Chiò, G. Logroscino, O. Hardiman et al., “Prognostic factors in ALS: a critical review,” Amyotrophic Lateral Sclerosis, vol. 10, no. 5-6, pp. 310–323, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. L. P. Rowland, “How amyotrophic lateral sclerosis got its name: the clinical-pathologic genius of Jean-Martin Charcot,” Archives of Neurology, vol. 58, no. 3, pp. 512–515, 2001. View at Google Scholar · View at Scopus
  19. L. C. Wijesekera and P. N. Leigh, “Amyotrophic lateral sclerosis,” Orphanet Journal of Rare Diseases, vol. 4, no. 1, article 3, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. A. E. Renton, A. Chiò, and B. J. Traynor, “State of play in amyotrophic later al sclerosis genetics,” Nature Neuroscience, vol. 17, pp. 17–23, 2014. View at Google Scholar
  21. S. Sathasivam, “Motor neurone disease: clinical features, diagnosis, diagnostic pitfalls and prognostic markers,” Singapore Medical Journal, vol. 51, no. 5, pp. 367–373, 2010. View at Google Scholar · View at Scopus
  22. V. Silani, S. Messina, B. Poletti et al., “The diagnosis of amyotrophic lateral sclerosis,” Archives Italiennes de Biologie, vol. 149, no. 1, pp. 5–27, 2011. View at Google Scholar · View at Scopus
  23. P. G. Ince, J. Lowe, and P. J. Shaw, “Amyotrophic lateral sclerosis: current issues in classification, pathogenesis and molecular pathology,” Neuropathology and Applied Neurobiology, vol. 24, no. 2, pp. 104–117, 1998. View at Publisher · View at Google Scholar · View at Scopus
  24. M. C. Dalakas, J. Hatazawa, R. A. Brooks, and G. Di Chiro, “Lowered cerebral glucose utilization in amyotrophic lateral sclerosis,” Annals of Neurology, vol. 22, no. 5, pp. 580–586, 1987. View at Google Scholar · View at Scopus
  25. J. Hatazawa, R. A. Brooks, M. C. Dalakas, L. Mansi, and G. Di Chiro, “Cortical motor-sensory hypometabolism in amyotrophic lateral sclerosis: a PET study,” Journal of Computer Assisted Tomography, vol. 12, no. 4, pp. 630–636, 1988. View at Google Scholar · View at Scopus
  26. B. P. Drayer, “Imaging of the aging brain. Part I: normal findings,” Radiology, vol. 166, no. 3, pp. 785–796, 1988. View at Google Scholar · View at Scopus
  27. A. C. Ludolph, K. J. Langen, M. Regard et al., “Frontal lobe function in amyotrophic lateral sclerosis: a neuropsychologic and positron emission tomography study,” Acta Neurologica Scandinavica, vol. 85, no. 2, pp. 81–89, 1992. View at Google Scholar · View at Scopus
  28. K. Ishikawa, H. Nagura, T. Yokota, and H. Yamanouchi, “Signal loss in the motor cortex on magnetic resonance images in amyotrophic lateral sclerosis,” Annals of Neurology, vol. 33, no. 2, pp. 218–222, 1993. View at Publisher · View at Google Scholar · View at Scopus
  29. Z. Shiozawa, K. Shindo, E. Ohta, K. Ohushi, M. Nagamatsu, and T. Nagasaka, “A concise overview of recent breakthroughs in imaging of ALS,” Amyotrophic Lateral Sclerosis, vol. 1, no. 2, pp. S3–S6, 2000. View at Publisher · View at Google Scholar · View at Scopus
  30. L. Mansi, M. C. Dalakas, G. DiChiro et al., “Evaluation of cerebral glucose metabolism in patients with amyotrophic lateral sclerosis (ALS) by [18F]-fluorodeoxyglucose (FDG) and positron emission tomography (PET),” Journal of Nuclear Medicine, vol. 24, article P21, 1983. View at Google Scholar
  31. S. Abrahams, L. H. Goldstein, J. J. M. Kew et al., “Frontal lobe dysfunction in amyotrophic lateral sclerosis: a PET study,” Brain, vol. 119, no. 6, pp. 2105–2120, 1996. View at Google Scholar · View at Scopus
  32. N. J. Patronas, G. Di Chiro, and B. H. Smith, “Depressed cerebellar glucose metabolism in supratentorial tumors,” Brain Research, vol. 291, no. 1, pp. 93–101, 1984. View at Publisher · View at Google Scholar · View at Scopus
  33. M.-O. Habert, L. Lacomblez, P. Maksud, G. E. L. Fakhri, J.-F. Pradat, and V. Meininger, “Brain perfusion imaging in amyotrophic lateral sclerosis: extent of cortical changes according to the severity and topography of motor impairment,” Amyotrophic Lateral Sclerosis, vol. 8, no. 1, pp. 9–15, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. Y. Jeong, K. C. Park, S. S. Cho et al., “Pattern of glucose hypometabolism in frontotemporal dementia with motor neuron disease,” Neurology, vol. 64, no. 4, pp. 734–736, 2005. View at Google Scholar · View at Scopus
  35. Y. Jeong, S. S. Cho, J. M. Park et al., “18F-FDG PET findings in frontotemporal dementia: an SPM analysis of 29 patients,” Journal of Nuclear Medicine, vol. 46, no. 2, pp. 233–239, 2005. View at Google Scholar · View at Scopus
  36. A. Cistaro, M. C. Valentini, A. Chiò et al., “Brain hypermetabolism in amyotrophic lateral sclerosis: a FDG PET study in ALS of spinal and bulbar onset,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, no. 2, pp. 251–259, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. G. Carrara, C. Carapelli, F. Venturi et al., “A distinct MR imaging phenotype in amyotrophic lateral sclerosis: correlation between T1 magnetization transfer contrast hyperintensity along the corticospinal tract and diffusion tensor imaging analysis,” American Journal of Neuroradiology, vol. 33, no. 4, pp. 733–739, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Cistaro, M. Pagani, A. Montuschi et al., “The metabolic signature of C9ORF72-related ALS: FDG PET comparison with nonmutated patients,” European Journal of Nuclear Medicine and Molecular Imaging, 2014. View at Publisher · View at Google Scholar
  39. S. Sestini, A. Castagnoli, and L. Mansi, “The new FDG brain revolution: the neurovascular unit and the default network,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 5, pp. 913–916, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Sestini, “Genetic studies of diseases: the neural basis of functional neuroimaging signal with positron and single-photon emission tomography,” Cellular and Molecular Life Sciences, vol. 64, no. 14, pp. 1778–1784, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. M. R. Turner, A. Cagnin, F. E. Turkheimer et al., “Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study,” Neurobiology of Disease, vol. 15, no. 3, pp. 601–609, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Johansson, H. Engler, G. Blomquist et al., “Evidence for astrocytosis in ALS demonstrated by [11C](l)-deprenyl-D2 PET,” Journal of the Neurological Sciences, vol. 255, no. 1-2, pp. 17–22, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. C. M. Lloyd, M. P. Richardson, D. J. Brooks, A. Al-Chalabi, and P. N. Leigh, “Extramotor involvement in ALS: PET studies with the GABA(A) ligand [11C]flumazenil,” Brain, vol. 123, no. 11, pp. 2289–2296, 2000. View at Google Scholar · View at Scopus
  44. M. R. Turner, A. Hammers, A. Al-Chalabi et al., “Distinct cerebral lesions in sporadic and “D90A” SOD1 ALS: studies with [11C]flumazenil PET,” Brain, vol. 128, no. 6, pp. 1323–1329, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. H. Takahashi, B. J. Snow, M. H. Bhatt, R. Peppard, A. Eisen, and D. B. Calne, “Evidence for a dopaminergic deficit in sporadic amyotrophic lateral sclerosis on positron emission scanning,” The Lancet, vol. 342, no. 8878, pp. 1016–1018, 1993. View at Publisher · View at Google Scholar · View at Scopus